Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2003 May 22

PMID 12759248

Citations 71

Authors

Raffaella Giavazzi

Barbara Sennino

Daniela Coltrini

Angela Garofalo

Romina Dossi

Roberto Ronca

Maria Pia Molinari Tosatti

Marco Presta

Affiliations

Soon will be listed here.

Abstract

Tumors express more than a single angiogenic growth factor. To investigate the relative impact of fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF) on tumor growth and neovascularization, we generated tumor cell transfectants differing for VEGF and/or FGF-2 expression. Human endometrial adenocarcinoma HEC-1-B-derived Tet-FGF-2 cells that express FGF-2 under the control of the tetracycline-responsive promoter (Tet-off system) were further transfected with a VEGF(121) anti-sense (AS-VEGF) cDNA. Next, Tet-FGF-2 and AS-VEGF/Tet-FGF-2 cells were transplanted subcutaneously in nude mice that received tetracycline or not in the drinking water. Simultaneous expression of FGF-2 and VEGF in Tet-FGF-2 cells resulted in fast-growing lesions characterized by high blood vessel density, patency and permeability, and limited necrosis. Blood vessels were highly heterogeneous in size and frequently associated with pericytes. Inhibition of FGF-2 production by tetracycline caused a significant decrease in tumor burden paralleled by a decrease in blood vessel density and size. AS-VEGF expression resulted in a similar reduction in blood vessel density associated with a significant decrease in pericyte organization, vascular patency, and permeability. The consequent decrease in tumor burden was paralleled by increased tumor hypoxia and necrosis. A limited additional inhibitory effect was exerted by simultaneous down-regulation of FGF-2 and VEGF expression. These findings demonstrate that FGF-2 and VEGF stimulate vascularization synergistically but with distinctive effects on vessel functionality and tumor survival. Blockade of either one of the two growth factors results in a decrease in blood vessel density and, consequently, in tumor burden. However, inhibition of the expression of VEGF, but not of FGF-2, affects also vessel maturation and functionality, leading to tumor hypoxia and necrosis. Our experimental model represents an unique tool to investigate anti-neoplastic therapies in different angiogenic environments.

Citing Articles

Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats.

Chen D, Chen J, Xia H, Chen X, Hu J, Wu G Front Pharmacol. 2024; 15:1498339.

PMID: 39697549 PMC: 11653107. DOI: 10.3389/fphar.2024.1498339.

Milestones in tumor vascularization and its therapeutic targeting.

de Palma M, Hanahan D Nat Cancer. 2024; 5(6):827-843.

PMID: 38918437 DOI: 10.1038/s43018-024-00780-7.

Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.

Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H Commun Chem. 2024; 7(1):3.

PMID: 38172256 PMC: 10764862. DOI: 10.1038/s42004-023-01084-0.

Fibroblast growth factor 2.

Nickle A, Ko S, Merrill A Differentiation. 2023; 139:100733.

PMID: 37858405 PMC: 11009566. DOI: 10.1016/j.diff.2023.10.001.

SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression.

Abouelnazar F, Zhang X, Zhang J, Wang M, Yu D, Zang X Cancer Cell Int. 2023; 23(1):149.

PMID: 37525212 PMC: 10388482. DOI: 10.1186/s12935-023-02985-9.

References

Statuto M, Ennas M, Zamboni G, Bonetti F, Pea M, Bernardello F . Basic fibroblast growth factor in human pheochromocytoma: a biochemical and immunohistochemical study. Int J Cancer. 1993; 53(1):5-10. DOI: 10.1002/ijc.2910530103. View

Gross J, Herblin W, Dusak B, CZERNIAK P, Diamond M, Sun T . Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst. 1993; 85(2):121-31. DOI: 10.1093/jnci/85.2.121. View

Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M . Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995; 55(5):1189-93. View

Dvorak H, Brown L, Detmar M, Dvorak A . Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146(5):1029-39. PMC: 1869291. View

Singh R, Gutman M, Bucana C, Sanchez R, Llansa N, Fidler I . Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995; 92(10):4562-6. PMC: 41984. DOI: 10.1073/pnas.92.10.4562. View

Drake C, Little C . Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci U S A. 1995; 92(17):7657-61. PMC: 41204. DOI: 10.1073/pnas.92.17.7657. View

Coltrini D, Gualandris A, Nelli E, Parolini S, Quarto N, Ziche M . Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res. 1995; 55(20):4729-38. View

Asahara T, Bauters C, Zheng L, Takeshita S, Bunting S, Ferrara N . Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995; 92(9 Suppl):II365-71. DOI: 10.1161/01.cir.92.9.365. View

Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1(1):27-31. DOI: 10.1038/nm0195-27. View

10.

Thomas K . Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996; 271(2):603-6. DOI: 10.1074/jbc.271.2.603. View

11.

Saleh M, Stacker S, Wilks A . Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 1996; 56(2):393-401. View

12.

Ferrara N, Chen H, Dowd M, Lu L, OShea K, Hillan K . Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996; 380(6573):439-42. DOI: 10.1038/380439a0. View

13.

Barleon B, Sozzani S, Zhou D, Weich H, Mantovani A, Marme D . Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996; 87(8):3336-43. View

14.

Cheng S, Huang H, Nagane M, Ji X, Wang D, Shih C . Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1996; 93(16):8502-7. PMC: 38701. DOI: 10.1073/pnas.93.16.8502. View

15.

Konerding M, Miodonski A, Lametschwandtner A . Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 1995; 9(4):1233-43; discussion 1243-4. View

16.

Leek R, Lewis C, Whitehouse R, Greenall M, Clarke J, Harris A . Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996; 56(20):4625-9. View

17.

Teicher B . A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Cancer Metastasis Rev. 1996; 15(2):247-72. DOI: 10.1007/BF00437479. View

18.

Kitadai Y, Ellis L, Tucker S, Greene G, Bucana C, Cleary K . Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol. 1996; 149(5):1541-51. PMC: 1865274. View

19.

Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain R . Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996; 93(25):14765-70. PMC: 26210. DOI: 10.1073/pnas.93.25.14765. View

20.

Ferrara N . The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1):4-25. DOI: 10.1210/edrv.18.1.0287. View